As of Apr 17
| -0.09 / -4.71%|
The 5 analysts offering 12-month price forecasts for CTi Biopharma Corp have a median target of 6.00, with a high estimate of 8.00 and a low estimate of 3.50. The median estimate represents a +229.67% increase from the last price of 1.82.
The current consensus among 5 polled investment analysts is to Buy stock in CTi Biopharma Corp. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.